QIAGEN Reports Solid Second Quarter 2010 Results

Qiagen N.V. / QIAGEN Reports Solid Second Quarter 2010 Results processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. * 11% Revenue growth at constant exchange rates * 10% Organic growth excluding H1N1 related effects * 25% Net income growth * $0.22 Adjusted EPS Venlo, The Netherlands, August 9, 2010 - QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) today announced the results of operations for the second quarter and the six-month period ended June 30, 2010. The reported net sales for the second quarter 2010 were in line with, and adjusted earnings per share were at the high end of, the Company's quarterly expectations as provided on May 4, 2010. Second Quarter 2010 Results +----------------------------------------------------------------------------+ | QIAGEN's Second Quarter 2010       | +----------------------------------------------------------------------------+ | in US$ millions, except per share information Q2 2010 Q2 2009 Growth | +----------------------------------------------------------------------------+ |         | | | | Net sales 262.7 240.2 9% | | | | Net sales at constant exchange rates 265.9 240.2 11% | | | | Net income 38.5 30.9 25% | | | | Net income, adjusted 52.5 48.3 9% | | | | EPS, adjusted( )(US$) 0.22 0.24   | | | |         | +----------------------------------------------------------------------------+ For information on the adjusted figures, please refer to the reconciliation table accompanying this release. The Company reported that consolidated net sales for its second quarter 2010 increased 9% to $262.7 million from $240.2 million in the same quarter of 2009. Excluding the unfavorable impact from foreign currency exchange rates, net sales for the second quarter 2010 would have increased 11% from the second quarter 2009. Reported operating income for the quarter decreased 9% to $42.8 million from $46.9 million in the same quarter of 2009, and net income for the quarter increased 25% to $38.5 million from $30.9 million in the same quarter of 2009. Diluted earnings per share for the second quarter increased to $0.16 in 2010 (based on 241.6 million weighted average shares and share equivalents outstanding) from $0.15 in 2009 (based on 203.8 million weighted average shares and share equivalents outstanding). Second quarter adjusted operating income increased 2% to $73.1 million in 2010 from $71.8 million in 2009, and second quarter 2010 adjusted net income increased 9% to $52.5 million from $48.3 million in 2009. Adjusted diluted earnings per share decreased to $0.22 in 2010 from $0.24 in 2009. These figures are adjusted for business integration, acquisition related and restructuring costs, a one-time tax benefit, purchased intangibles amortization and share based compensation. Six-Month Period 2010 Results For the six-month period ended June 30, 2010, net sales increased 14% to $527.1 million compared to $461.1 million in the respective period of 2009. Operating income as reported for the six months ended June 30, 2010 increased 4% to $87.5 million from $83.9 million for the same period in 2009. Net income increased 29% to $71.5 million from $55.6 million in 2009, and diluted earnings per share increased to $0.30 in 2010 from $0.27 in 2009. On an adjusted basis, operating income for the six-month period ended June 30, 2010 increased 12% to $146.7 million in 2010 from $130.9 million in 2009, and adjusted net income increased 15% to $101.9 million from $88.5 million. Adjusted diluted earnings per share in the six months ended June 30, 2010 decreased to $0.42 per share from $0.44 per share in the same period of 2009. QIAGEN's second quarter and six-month period 2010 results include the results of operations from the Company's recent acquisitions, the most significant of which were SABiosciences Corporation, acquired in December 2009 and DxS Ltd., acquired in September 2009. Reconciliations of reported results determined in accordance with generally accepted accounting principles (GAAP) to adjusted results are included in the tables accompanying this release. "QIAGEN experienced a successful second quarter," said Peer Schatz, QIAGEN's Chief Executive Officer. "We met our quarterly revenue expectations as communicated in our previous quarterly conference call and came in on the high end of our adjusted EPS expectations. Our markets remain stable across our customer segments and show promising growth opportunities. "We achieved a substantial increase in product sales to our customers in molecular diagnostics, applied markets, the pharmaceutical industry and in academia and remain very well prepared to exploit further growth opportunities in our target markets. "Molecular diagnostics remains our strongest revenue driver even when considering the impacts related to swine flu testing in 2009. The market for our profiling assays and solutions remains very solid. The market for our prevention assays (primarily HPV screening), continues to benefit from our market adoption initiatives in the United States despite what is believed to be a temporary extension of doctor visit intervals. Anticipated future healthcare policies and reimbursement schemes world-wide promise a healthy outlook for this market segment. The applied testing markets show excellent growth opportunities. Our recent addition of more than 70 new food safety tests to our assay technologies portfolio and the addition of a portfolio of forensic assays position QIAGEN for further strong growth in the applied testing customer class. In the pharmaceutical industry we observed a continuing trend to focus on our sample and assay solutions that enable molecular selection, guidance, progression and recurrence during the drug development process. With our portfolio of sample and assay technologies and our broad portfolio of instrument platforms we believe we are well positioned to address the needs coming with molecular based drug development. In addition we recently launched our new SABiosciences portfolio through our QIAGEN sales channels, thereby enabling pharmaceutical and academic partners to advance biomarker discovery and research. "We feel very well prepared to take advantage of the growth opportunities in our target markets and are on track to achieve our annual targets." "We are pleased with our financial performance in this second quarter of 2010. Reported revenues met, and adjusted earnings per share were at the high end of, our expectations for the second quarter of 2010 as set in our most recent quarterly conference call in early May," said Roland Sackers, QIAGEN's Chief Financial Officer. "Revenue growth for the second quarter was 9% (11% under constant exchange rates). Organic growth excluding H1N1 related revenues was strong at 10% and we realized a positive contribution from acquisitions of 7%. "Our consumable portfolio represented approximately 85% of our total net sales and contributed approximately 10% growth at constant exchange rates. QIAGEN's instrumentation products represented approximately 14% of our total net sales and grew with approximately 10% at constant exchange rates. The largest revenue share we recorded in the second quarter 2010 was in sales to customers in molecular diagnostics (approximately 47% of total revenues) followed by sales to customers in academia (approximately 24% of total revenues), in the pharmaceutical industry (approximately 22% of total revenues) and in applied testing markets (approximately 7% of total revenues). "We are reiterating our guidance for the fiscal year 2010. Based on foreign currency exchange rates as of January 31, 2010, this guidance targets revenues between $1,120 and $1,170 million and adjusted diluted earnings per share between $0.90 and $0.96. The guidance on EPS, adjusted does not include a negative contribution for 2010 of approximately US$0.01 from the acquisition of all rights to a portfolio of molecular food safety tests developed by the Institute for Product Quality (ifp) in May 2010." QIAGEN - Sample and Assay Technologies Highlights * QIAGEN extended its development agreement with Genome Diagnostics targeting the development and commercialization of a series of new assays to detect genetic variations in the so called Human Leukocyte Antigen (HLA) complex. These assays are increasingly used in personalized healthcare (PHC). The assays will include tests based on QIAGEN's proprietary "Pyrosequencing" technology which enables fast, cost effective and accurate analysis of HLA sequences, and allows for direct detection of previously unknown polymorphisms. QIAGEN believes that this collaboration will further expand the Company's testing portfolio for the early detection of diseases and individualized treatment of patients - thereby strengthening QIAGEN's molecular diagnostics offering for applications in prevention and personalized healthcare (PHC). * QIAGEN acquired all rights to a portfolio of 70 molecular food safety tests developed by the Institute for Product Quality (ifp). The tests are based on real-time PCR (Polymerase Chain Reaction) technology and cover a broad range of molecular targets including genetic, bacterial, viral and other contaminants of food products. The tests can be fully automated using QIAGEN's instrument platforms such as the QIAsymphony and the Rotor-Gene Q. The transaction enables QIAGEN to offer complete solutions for all major applications in the food safety testing segment, covering entire workflows from the processing of primary samples to the final testing result. The first test kits are expected to be available through QIAGEN in the fourth quarter of 2010. * QIAGEN added a range of Human Identity (HID) PCR assays for human identity testing applications in forensics to its assay technologies portfolio through the acquisition of various assets from a leading forensics assay supplier in Europe. Our new human ID assay portfolio includes IP, know-how and co-exclusive rights to innovative software suites for analysis of STR genotyping data. The assay portfolio features comprehensive coverage of international STR (short tandem repeat) marker standards, including the new European Standard Set (ESS) as defined by the Council of the European Union in the effort to harmonize Europe's national DNA databases. * QIAGEN announced a donation of one million HPV tests to low-income countries over five years, following the April 2009 publication of study results in The New England Journal of Medicine. The control group in the study had no screening, which is the standard of care in many parts of India. From the company's "one million test" donation program, QIAGEN allocated first grants, including a donation of approximately 26,000 human papillomavirus (HPV) tests to the Nargis Dutt Memorial Cancer Hospital in India for cervical cancer screening. * QIAGEN completed the European certification of its careHPV(TM) Test to bring human papillomavirus (HPV) testing to public-health programs in low-resource, developing countries. The CE conformity marking ("Conformité Européenne") certifies that the careHPV Test has met European Union consumer safety and health requirements, allowing the test to be distributed in developing countries that recognize the CE mark. * QIAGEN launched 19 new products/product groups in the area of Sample & Assay Technologies including the SABiosciences portfolio for gene and pathway analysis as well as a number of molecular diagnostic assays including a CE-labeled artus real time PCR assay for the detection of the Herpes-Simplex virus and the EASYartus PCR assay for the detection of the Cytomegalus virus. Conference Call and Webcast Details Detailed information on QIAGEN's business and financial performance will be presented during its conference call on August 10, 2010 at 9:30am ET. The corresponding presentation slides will be available for download on the Company's website at www.qiagen.com/goto/ConferenceCall. A webcast of the conference call will also be available at www.qiagen.com/goto/ConferenceCall. Use of Adjusted Results QIAGEN has regularly reported adjusted results to give additional insight into its financial performance as well as considered results on a constant currencies basis. Adjusted results should be considered in addition to the reported results prepared in accordance with generally accepted accounting principles, but should not be considered as a substitute. The Company believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with the Company's competitors and its own prior periods. Reconciliations of reported results to adjusted results are included in the tables accompanying this release. About QIAGEN QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make these isolated biomolecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The Company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the first FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 3,500 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/. Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between business segments, the commercial development of markets for our products in applied testing, personal healthcare, clinical research, proteomics, women's health/HPV testing, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy, changing relationships with customers, suppliers and strategic partners, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets, and other factors), our ability to obtain regulatory approval of our infectious disease panels, difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate and protect its products from competitors' products, market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). ### QIAGEN N.V. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited)       Three months ended u e 30, (in US$ thousands, except per share data) --------------------       2010   2009 ---------- --------- Net sales   262,718   240,156   Cost of sales   89,912   80,656 ---------- --------- Gross profit   172,806   159,500 ---------- --------- Operating expenses:   Research and development   29,423   24,950   Sales and marketing   66,255   59,039   General and administrative, integration and other   28,438   24,618   Acquisition-related intangible amortization   5,840   4,011 ---------- --------- Total operating expenses   129,956   112,618 ---------- --------- Income from operations   42,850   46,882 ---------- --------- Other income (expense):   Interest income   1,501   678   Interest expense    (7,669)    (7,302)   Other income, net   2,858   778 ---------- --------- Total other expense    (3,310)    (5,846) ---------- --------- Income before provision for income taxes   39,540   41,036 Provision for income taxes   1,020   10,107 ---------- --------- Net income   38,520   30,929   Weighted average number of diluted common shares   241,636   203,785   Diluted net income per common share    $ 0.16    $ 0.15   Diluted net income per common share, adjusted    $ 0.22    $ 0.24 QIAGEN N.V. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited)       Six months ended u e 30, (in US$ thousands, except per share data) ----------------------       2010   2009 ----------- ---------- Net sales   527,082   461,089   Cost of sales   181,064   155,140 ----------- ---------- Gross profit   346,018   305,949 ----------- ---------- Operating expenses:   Research and development   61,021   50,593   Sales and marketing   130,690   115,137   General and administrative, integration and other   54,778   48,406   Acquisition-related intangible amortization   11,998   7,902 ----------- ---------- Total operating expenses   258,487   222,038 ----------- ---------- Income from operations   87,531   83,911 ----------- ---------- Other income (expense):   Interest income   2,190   1,863   Interest expense    (13,923)    (14,732)   Other income, net   5,093   2,558 ----------- ---------- Total other expense    (6,640)    (10,311) ----------- ---------- Income before provision for income taxes   80,891   73,600 Provision for income taxes   9,358   17,987 ----------- ---------- Net income   71,533   55,613   Weighted average number of diluted common shares   241,780   203,476   Diluted net income per common share    $ 0.30    $ 0.27   Diluted net income per common share, adjusted    $ 0.42    $ 0.44 QIAGEN N.V. CONDENSED CONSOLIDATED BALANCE SHEETS (in US$ thousands, except par value)   June 30,   December 31,           2010   2009 --------------- -------------- Assets     (unaudited) Current Assets:   Cash and cash equivalents        844,209        825,557   Short-term investments         74,000         40,000   Accounts receivable, net        189,958        193,737   Income taxes receivable         14,714         12,907   Inventories, net        117,808        130,851   Prepaid expenses and other          80,456         96,893   Deferred income taxes         31,605         33,525 --------------- --------------       Total current assets       1,352,750       1,333,470 --------------- -------------- Long-Term Assets:   Property, plant and equipment, net        303,381        317,467   Goodwill       1,316,955       1,337,064   Intangible assets, net        713,664        752,296   Deferred income taxes         29,202         26,387   Other assets         51,833         29,780 --------------- --------------       Total long-term assets       2,415,035       2,462,994 --------------- -------------- --------------- --------------     Total assets       3,767,785       3,796,464 Liabilities and Shareholders' Equity Current Liabilities:   Accounts payable         49,007         43,775   Accrued and other liabilities        188,653        248,699   Income taxes payable         13,672         10,727   Current portion of long-term debt         50,977         50,000   Current portion of capital lease obligations          3,346          3,417   Deferred income taxes         16,356         18,912 --------------- --------------       Total current liabilities        322,011        375,530 --------------- -------------- Long-Term Liabilities:   Long-term debt, net of current portion        871,783        870,000   Capital lease obligations, net of current         24,353         27,554 portion   Deferred income taxes        201,877        212,690   Other liabilities         13,218         19,521 --------------- --------------       Total long-term liabilities       1,111,231       1,129,765 --------------- -------------- Shareholders' Equity:   Common shares, EUR .01 par value:     Authorized--410,000 shares     Issued and outstanding--232,703 shares       in 2010 and 232,074 shares in 2009          2,720          2,711     Additional paid-in-capital       1,637,656       1,622,733     Retained earnings        687,112        615,579     Accumulated other comprehensive income          7,055         50,146 --------------- --------------       Total shareholders' equity       2,334,543       2,291,169 --------------- -------------- --------------- --------------     Total liabilities and shareholders' equity       3,767,785       3,796,464 QIAGEN N.V. RECONCILIATION OF REPORTED TO ADJUSTED FIGURES (unaudited) Three months ended June 30, 2010 (in US$ millions, except EPS data)     Gross Operating Pre-tax Income Net Diluted Net Sales Profit Income Income Tax Income EPS* ---------------------------------------------------------------- Reported results 262.7 172.8 42.8 39.5 (1.0) 38.5  $ 0.16 Adjustments: Business integration, acquisition related and restructuring costs and tax benefit from   restructuring - -        5.5 5.5 (7.7) (2.2)  (0.01) Purchased intangibles   amortization -  15.3       21.1 21.1 (7.5) 13.6 0.06 Share-based   compensation - 0.3        3.7 3.7 (1.1) 2.6 0.01 ---------------------------------------------------------------- Total   adjustments - 15.6       30.3 30.3 (16.3) 14.0   0.06 ---------------------------------------------------------------- Adjusted results 262.7 188.4 73.1 69.8 (17.3) 52.5  $ 0.22 *  Using 241.6 M diluted shares Three months ended June 30, 2009 (in US$ millions, except EPS data)     Gross Operating Pre-tax Income Net Diluted Net Sales Profit Income Income Tax Income EPS* ---------------------------------------------------------------- Reported results 240.2 159.5 46.9 41.0 (10.1) 30.9  $ 0.15 Adjustments: Business integration, acquisition related and restructuring   costs - 0.3        4.9 4.9 (1.6) 3.3 0.02 Purchased intangibles   amortization - 13.2       17.2 17.2 (6.0) 11.2 0.06 Share-based   compensation - 0.2        2.8 2.8 (0.8) 2.0 0.01 Acquisition related write-off of prepaid   expenses - -          - 1.2 (0.3) 0.9 - ---------------------------------------------------------------- Total                      24.9   adjustments - 13.7 26.1 (8.7) 17.4 0.09 ---------------------------------------------------------------- Adjusted results 240.2 173.2 71.8 67.1 (18.8) 48.3  $ 0.24 *  Using 203.8 M diluted shares QIAGEN N.V. RECONCILIATION OF REPORTED TO ADJUSTED FIGURES (unaudited) Six months ended June 30, 2010 (in US$ millions, except EPS data) Net Gross Operating Pre-tax Net Diluted     Sales Profit Income Income Income Tax Income   EPS* ----------------------------------------------------------------         $ Reported results 527.1 346.0 87.5 80.9 (9.4) 71.5   0.30 Adjustments: Business integration, acquisition related and restructuring costs and tax benefit from   restructuring -  0.8 10.5 10.5 (12.0) (1.5)   (0.01) Purchased intangible   amortization -  30.4 42.4 42.4 (15.0) 27.4     0.11 Share-based   compensation -  0.4 6.3 6.3 (1.8) 4.5     0.02 ---------------------------------------------------------------- Total   adjustments -  31.6 59.2 59.2 (28.8) 30.4     0.12 ----------------------------------------------------------------              $ Adjusted results 527.1 377.6 146.7 140.1 (38.2) 101.9   0.42 *  Using 241.8 M diluted shares Six months ended June 30, 2009 (in US$ millions, except EPS data) Net Gross Operating Pre-tax Net Diluted     Sales Profit Income Income Income Tax Income   EPS* ----------------------------------------------------------------        $ Reported Results 461.1 305.9 83.9 73.6 (18.0) 55.6   0.27 Adjustments:   Business integration, acquisition related and restructuring costs -  0.5 7.9 7.9 (2.5) 5.4     0.03   Purchased intangible amortization -  26.2 34.1 34.1 (11.9) 22.2     0.11 Share-based   compensation -  0.5 5.0 5.0    (1.5)    3.5     0.02   Acquisition related write-off of prepaid expenses and other asset impairment -  -  -  2.7 (0.9) 1.8     0.01 ----------------------------------------------------------------   Total adjustments -  27.2 47.0 49.7     (16.8) 32.9     0.17 ---------------------------------------------------------------- Adjusted results              $ 461.1 333.1 130.9 123.3 (34.8) 88.5   0.44 *  Using 203.5 M diluted shares Contacts: Dr. Solveigh Mähler Dr. Thomas Theuringer Director Investor Relations Director Public Relations QIAGEN N.V. QIAGEN N.V. +49 2103 29 11710 +49 2103 29 11826 e-mail:solveigh.maehler@qiagen.com e-mail:thomas.theuringer@qiagen.com Albert F. Fleury Director Corporate Finance and Investor Relations North America QIAGEN N.V. +1 301 944 7028 e-mail:albert.fleury@qiagen.com [HUG#1436757] --- End of Message --- Qiagen N.V. Spoorstraat 50 KJ Venlo Netherlands Listed: Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Bayerische Börse München, Freiverkehr in Niedersächsische Börse zu Hannover, Prime Standard in Frankfurter Wertpapierbörse; This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction for further distribution is prohibited. Source: Qiagen N.V. via Thomson Reuters ONE